With Dr. Tomasz (Tom) Beer MD – Chief Medical Officer for MCED at Exact Sciences

From precision oncology pioneer to leading the shift toward population-scale early detection via blood-based tech. The future of cancer care: intercepting it before it’s too late.

Dr. Tomasz Beer, MD is a nationally recognized medical oncologist and clinical research leader who serves as Chief Medical Officer for Multi-Cancer Early Detection at ‪@ExactSciences‬ Corporation (https://www.exactsciences.com/), a molecular diagnostics company focused on the eradication of cancer by preventing it, detecting it earlier, and guiding personalized treatment.

Before joining Exact Sciences, Dr. Beer spent decades at the forefront of academic oncology, including serving as Deputy Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, where he helped build one of the country’s leading precision cancer programs.

A prostate cancer specialist by training, Dr. Beer has led numerous clinical trials, authored hundreds of peer-reviewed publications, and been a driving force in advancing biomarker-guided cancer therapy. His career has spanned the evolution of oncology—from empiric chemotherapy to precision medicine and now toward population-scale cancer detection.

Today, Dr. Beer is helping lead one of the most ambitious shifts in cancer care: moving from late-stage treatment to early detection across multiple tumor types through advanced molecular diagnostics and blood-based screening technologies.

#MultiCancerEarlyDetection #CancerInterception #LiquidBiopsy #PrecisionOncology #CancerPrevention #Immunotherapy #EarlyDetection #OncologyInnovation #CancerResearch #MCED